Skip to content

Feasibility study of early diagnosis markers for acute kidney injury caused by cisplatin chemotherapy

Feasibility study of early diagnosis markers for acute kidney injury caused by cisplatin chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056781
Enrollment
Unknown
Registered
2022-02-16
Start date
2022-02-28
Completion date
Unknown
Last updated
2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney injury

Interventions

Gold Standard:1. Serum creatinine rises by 0.3mg/dl (26.5µmol/L) within 48 hours
2. Within 7 days of known or assumed renal impairment, serum creatinine rises to> 1.5 times the baseline value
3. Urine volume <0.5ml /(kg·h) for 6h.
Index test:Scr?KIM-1?NGAL

Sponsors

The Fifth Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients who are about to receive intravenous cisplatin for the first time as a cancer chemotherapy regimen; (2) Age = 18 years old, no gender limit; (3) The patient understands and is willing to sign a written consent document; (4) The patient may be receiving combined treatment with cisplatin and other chemotherapy drugs.

Exclusion criteria

Exclusion criteria: (1) Previously received cisplatin therapy; (2) Patients who have previously received dialysis or other renal replacement therapy; (3) Individuals who do not agree to donate peripheral blood or have obvious discomfort in blood sampling; (4) Kidney diseases that do not meet hemodialysis standards, such as chronic kidney disease.

Design outcomes

Primary

MeasureTime frame
serum creatinine;kidney injury molecule-1;neutropil gelatinase-associated lipocalin;

Countries

China

Contacts

Public Contactyingbo dai
daiyb@mail.sysu.edu.cn13786141691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026